The Latest Cardiac and Vascular News
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 […]
PARIS and MONTMORENCY, France, Dec. 20, 2024 (GLOBE NEWSWIRE) — Balt, a global medical device leader in interventional neuroradiology, announces that it has secured €355 million in financing from a group of leading institutional investors and banks to refinance existing debt, accelerate product innovation, expand production capacity, and enhance development of key growth markets.
SILVER SPRING, Md., Dec. 20, 2024 /PRNewswire/ — The U.S. Food and Drug Administration approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization (restoration of blood flow)…
Roivios Initiates Landmark Study to Demonstrate Safety and Efficacy of an Innovative Renal Assist Device for Cardiac Surgery Patients With Kidney Disease NASSAU, Bahamas, Dec. 19, 2024 /PRNewswire/ — Roivios, a pioneering clinical-stage medical device company dedicated to revolutionizing…
SAN FRANCISCO–(BUSINESS WIRE)–ŌURA, the company behind Oura Ring, the world’s leading smart ring, today announced the completion of a $200 million Series D funding round. Fidelity Management & Research Company and Dexcom, the global leader in glucose biosensing, participated in the round. The investment raises the company’s valuation to $5.2 […]
– Exclusive rights secured related to the development of a potential disease-modifying therapeutic for cardiovascular disease. CHICAGO, Dec. 19, 2024 /PRNewswire/ — Xentria, Inc. (Xentria), a clinical-stage biotherapeutics company focused on advancing drug development to address unmet…
TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today’s standard of care – saving lives and reducing disability Following the Phase 1 safety study, TargED intends to further develop TGD001 in patients with AIS and iTTP…
December 18, 2024 07:35 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. […]
HUNTINGTON BEACH, Calif.–(BUSINESS WIRE)–BiVACOR, a clinical-stage medical device company, announced today, the successful completion of the first phase of the FDA Early Feasibility Study, with five patients receiving the BiVACOR Total Artificial Heart (TAH) between July and November 2024. The study evaluates the safety and performance of the BiVACOR TAH System […]
Pilot study testing innovative agent designed to provide guideline-concordant education believed to be the first clinical study to evaluate an AI Agent with actual AFib patients SAN DIEGO, Dec. 18, 2024 /PRNewswire/ — Lucia Health Guidelines announces the enrollment of the first eight…
